Flow chart. * In the 300 mg QD cohort, one patient had protocol violation and no exact administration time of BPI-9016M, the sparse PK data of four patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS. # In the 450 mg QD cohort, the sparse PK data of five patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS. In the 600 mg QD cohort, one patient discontinued over two-week treatment of BPI-9016M due to the poor compliance, the sparse PK data of two patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS
